



维亚生物科技控股集团  
Viva Biotech Holdings  
(Stock Code: 1873.HK)

NEWSLETTER Issue 1  
Jul-Oct

**Listing Date**

2019.05.09

**Price (2019.10.22)**

HKD 4.96

**Volume**

1.74M

**17 WK**

HKD 3.356-5.08

**Market Cap (2019.10.22)**

HKD 7.86B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.



**Company news**

**VIVA Biotech Annual Gala Dinner 2019 held in Boston**

On Oct. 1st, 2019, Viva Biotech successfully held an Annual Gala Dinner in Boston, US. This event was well received and attracted over 100 attendants representing the Biotech/Pharma life science industry from Boston and the surrounding area. All participants enjoyed a fun and relaxing evening of networking and communicating. Many of Viva Biotech's loyal patrons have had many years of fruitful collaborations with Viva Biotech. They had lots of compliments on Viva Biotech's best-in-the-class Gene-to-Protein and Gene-to-Structure platforms, as well as cutting-edge ASMS screening technology, and see the endless possibilities in the future of Viva Biotech's chemistry capabilities as well as incubation and investment activities.



**Viva Biotech Chengdu New Drug Incubation and Biological Production R&D Center Laid in Wenjiang**

On September 24th, the ground-breaking ceremony of Viva Biotech Chengdu new drug incubation and biological production R&D center was held in Wenjiang district. Viva Biotech Chengdu is the fourth innovative drug base after Zhangjiang Shanghai, USA Boston and Zhejiang Jiaxing. It is an important part of Viva Biotech's industry value-chain expansion and global strategic layout. After the completion of the project, it will become a modern scientific research and production center integrating new drug research and development, achievement transformation and production.



## Viva Biotech CBO Dr. David Xu Attended RESI China Cross-border Cooperation Symposium in Boston

On September 11, at the RESI series meetings held in Boston, Dr. David Xu, chief business officer of Viva Biotech and director of Viva Biotech innovation center, attended the symposium on "China cross-border cooperation". The main topic of the symposium was why China became a hot spot for early drug discovery.



## Viva Biotech Announced 2019 Interim Results



Dr. Chen Mao, Chairman, Chief Executive Officer and Executive Director of Viva Biotech Holdings (Left) as well as Hua Fengmao, Executive Director and Chief Financial Officer (Right) attended the interim results announcement and introduced the group's performance in the first half of the year

On August 28, 2019, Viva Biotech Holdings announced its first interim results after listing in Hong Kong. The Group's revenue recorded a significant increase of 83.9% to approximately RMB142.3 million compared with the same period last year, and the net profit excluding extraordinary profit or loss increased by 47.4% to approximately RMB98.6 million. Basic adjusted Non-IFRS earnings per share recorded RMB0.08, and the Board of Directors recommended an interim dividend of HK\$0.5 cents per share.

Looking forward, Dr. Chen Mao said: "Viva Biotech will grasp the historical opportunity by enhancing operating efficiency, reinforcing talent recruitment and introducing new technologies, thus to proactively establish and constantly improve the sustainability and scalability of our technology platforms and incubation platforms. The Company will establish a win-win ecological circle through the 'Service + Capital' multi-dimensional layout alongside the industry chain integration. We will strive to realize sustainable and quality growth to maximize the return for investors."

## Viva Biotech Supported the SABPA E-Club Medicinal Chemistry Symposium

In August 2019, the Sino-American Biotechnology and Pharmaceutical Professionals Association (SABPA) E-Club event sponsored by Viva Biotech was held in San Diego, California. The symposium attracted over 100 professionals including medicinal chemists, drug developers and more who represented many of the prestigious biotech and pharmaceutical companies in San Diego. Viva Biotech was represented by Yinghong Gao, the Executive Director of Business Development and Associate Business Partner for Viva Biotech's US based partnerships. Ms. Gao gave a presentation on "SBDD, FDBB, ASMS and SPR-inspired Medicinal Chemistry".



## Market Recognition

**Top 100 Companies of China Pharmaceutical Industry was Announced, Viva Biotech Listed in the Top 20 of China CRO Enterprise in 2018**

On July 15, 2019, Menet and Medical Economic Reporter jointly released the "2018's top 100 companies of China pharmaceutical industry", Viva Biotech was listed in the Top 20 of China CRO (including CDMO) Enterprise in 2018. "Top 100 Companies of China pharmaceutical industry" has been consecutively published for more than 10 years, as one of the most influential and authoritative pharmaceutical lists in China.


**Pharmaceutical Executive Magazine Interviewed Dr. Chen Mao**

On September 2, 2019, Dr. Chen Mao, Chairman, Chief Executive Officer and Executive Director of Viva Biotech Holdings, interviewed by Pharmaceutical Executive magazine and introduced Viva Biotech, Biotech's business model and currently incubating projects. Dr. Chen Mao said that over the past 11 years, Viva Biotech has achieved industry-leading project results and has an excellent reputation in the industry, which he is proud of. The report has been published on the Pharmaceutical Executive website and widely reprinted by the media.

For the full text of this interview, please click on the link:

<https://pharmaboardroom.com/interviews/chenev-mao-chairman-ceo-viva-biotech-china/>





## Research & Development Process



### **Anji pharma is about to Start a Global Phase III Clinical Research of Type 2 Diabetic Nephropathy**

Anji pharma, incubated by Viva Biotech, has officially announced that it has won the global license to develop an innovative OAD (oral antidiabetic drug), Metformin DR, and planned to start a global multicentre phase III clinical trial for patients with type 2 diabetic nephropathy this year. The phase III clinical trial research programme has been approved by the FDA.



### **Dogma Therapeutics Disclosed its Research and Development Program on Oral PCSK9 Inhibitor**

Dogma Therapeutics, incubated by Viva Biotech, has disclosed its research and development program on oral PCSK9 inhibitor. The company says the program has been speeded up by the unique collaboration with Charles River and Viva Biotech.



### **Arthroasi Independently Developed Blood-Uric-Acid-Lowering Agent Which Can Control Gout Attack Long Effectively and Dissolve Tophus and Will Enter Phase II Clinical Trial at the End of This Year**

As a seed round and B round investor, Viva Biotech participated in Arthroasi's early development of AR882, a new generation of uric acid excretion promoter. AR882 is expected to be the most effective clinical blood-uric-acid-lowering agent. So far, single administration (SAD), multiple administration (MAD) and combined administration with Febuxostat have been completed in clinical phase I. Clinical phase II is in preparation, and corresponding preclinical toxicology and safety tests are also in progress.

## Investments Progress



### **QureBio Completed it's Series A Funding**

QureBio, invested and incubated by Viva Biotech, has announced that the completion of series A financing. QureBio is a research and development company, focusing on the innovation of macromolecular biological drugs, aim to develop new therapeutic drugs for benefiting patients in the fields of refractory cancer, autoimmune diseases and metabolic diseases all over the world. In 2017, QureBio received angel round investment from Viva Biotech and started their experiment.



### **VivaVision Biopharma Completed the Series C Funding of RMB 65 Million to Accelerate the Clinical Development of Innovative Ophthalmic Medicine**

VivaVision Biopharma (Shanghai) co., LTD., jointly established by the founder Dr. Wang Shen and Viva BioInnovator, successfully completed a new round of funding of RMB 65 million. The funding will be used to support the clinical research in US of VVN001, the company's self-developed innovative medicine project for dry eye disease. VivaVision Biopharma is committed to the R&D of innovative medicine for ophthalmic diseases, the company has established a leading product pipeline as well as a world class ophthalmic R&D team.

## Investor & Media Enquiries

Viva Biotech Holdings website: [www.vivabiotech.com.cn](http://www.vivabiotech.com.cn)

For further information, please contact:

Email : [VivaBiotech.hk@pordahavas.com](mailto:VivaBiotech.hk@pordahavas.com)

Tel : 852-3150 6788

